FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2611492720> ?p ?o ?g. }

• W2611492720 endingPage "H124" @default.
• W2611492720 startingPage "H114" @default.
• W2611492720 abstract "Heart failure (HF) patients demonstrate impaired pulmonary, circulatory, and nervous system responses to exercise. While HF demonstrates prolonged [time constant (τ)] pulmonary O 2 uptake (V̇o 2 ) on-kinetics, contributing to exercise intolerance, it is unknown whether abnormal V̇o 2 kinetics couple with ventilatory and circulatory dysfunction secondary to impaired group III/IV afferents in HF. Because lower lumbar intrathecal fentanyl inhibits locomotor muscle afferents, resulting in improved exercise ventilation and hemodynamics, we tested these hypotheses: HF will demonstrate 1) rapid V̇o 2 on-kinetics and 2) attenuated steady-state V̇o 2 amplitude and O 2 deficit (O 2 def) during exercise with fentanyl versus placebo. On separate visits (randomized), breath-by-breath V̇o 2 was measured in HF (ejection fraction: 27 ± 6%, New York Heart Association class I–III) and age- and sex-matched controls (both n = 9, ages: 60 ± 6 vs. 63 ± 8 yr, P = 0.37) during cycling transitions at 65% peak workload (78 ± 24 vs. 115 ± 39 W, P < 0.01) with intrathecal fentanyl or placebo. Regardless of group or condition, optimal phase II (primary component) curve fits reflected a phase I period equal to 35 s (limb-to-lung timing) via single-exponential functions. Condition did not affect steady-state V̇o 2 , the phase II τ of V̇o 2 , or O 2 def within controls ( P > 0.05). Without differences in steady-state V̇o 2 , reduced O 2 def in fentanyl versus placebo within HF (13 ± 4 vs. 22 ± 15 ml/W, P = 0.04) was accounted for by a rapid phase II τ of V̇o 2 in fentanyl versus placebo within HF (45 ± 11 vs. 57 ± 14 s, P = 0.04), respectively. In an integrative manner, these data demonstrate important effects of abnormal locomotor muscle afferents coupled to pulmonary and circulatory dysfunction in determining impaired exercise V̇o 2 in HF. Effects of abnormal muscle afferents on impaired exercise V̇o 2 and hence exercise intolerance may not be discernable by independently assessing steady-state V̇o 2 in HF. NEW & NOTEWORTHY Inhibition of locomotor muscle afferents results in rapid primary-component O 2 uptake (V̇o 2 ) on-kinetics accounting for the decreased O 2 deficit in heart failure (HF). This study revealed that abnormal musculoskeletal–neural afferents couple with pulmonary and circulatory dysfunction to provoke impaired exercise V̇o 2 in HF. Steady-state V̇o 2 cannot properly phenotype abnormal muscle afferent contributions to impaired exercise V̇o 2 in HF." @default.
• W2611492720 created "2017-05-12" @default.
• W2611492720 creator A5017952950 @default.
• W2611492720 creator A5024268930 @default.
• W2611492720 creator A5053447036 @default.
• W2611492720 creator A5078998559 @default.
• W2611492720 creator A5082946065 @default.
• W2611492720 date "2017-07-01" @default.
• W2611492720 modified "2023-10-15" @default.
• W2611492720 title "V̇o2 kinetics associated with moderate-intensity exercise in heart failure: impact of intrathecal fentanyl inhibition of group III/IV locomotor muscle afferents" @default.
• W2611492720 cites W1513335564 @default.
• W2611492720 cites W1667010032 @default.
• W2611492720 cites W1682043670 @default.
• W2611492720 cites W1914761702 @default.
• W2611492720 cites W1977148027 @default.
• W2611492720 cites W1979083003 @default.
• W2611492720 cites W1981864649 @default.
• W2611492720 cites W1984302000 @default.
• W2611492720 cites W1992982295 @default.
• W2611492720 cites W2000930422 @default.
• W2611492720 cites W2001292782 @default.
• W2611492720 cites W2004114044 @default.
• W2611492720 cites W2009941286 @default.
• W2611492720 cites W2017524358 @default.
• W2611492720 cites W2017652833 @default.
• W2611492720 cites W2022229829 @default.
• W2611492720 cites W2022407615 @default.
• W2611492720 cites W2022579740 @default.
• W2611492720 cites W2037557484 @default.
• W2611492720 cites W2038803285 @default.
• W2611492720 cites W2043086870 @default.
• W2611492720 cites W2045769066 @default.
• W2611492720 cites W2064550842 @default.
• W2611492720 cites W2074602210 @default.
• W2611492720 cites W2077988634 @default.
• W2611492720 cites W2082351345 @default.
• W2611492720 cites W2092761402 @default.
• W2611492720 cites W2105278937 @default.
• W2611492720 cites W2111900425 @default.
• W2611492720 cites W2116250696 @default.
• W2611492720 cites W2117391624 @default.
• W2611492720 cites W2123426860 @default.
• W2611492720 cites W2125078269 @default.
• W2611492720 cites W2125291255 @default.
• W2611492720 cites W2143015249 @default.
• W2611492720 cites W2143479480 @default.
• W2611492720 cites W2145139856 @default.
• W2611492720 cites W2153158559 @default.
• W2611492720 cites W2153675496 @default.
• W2611492720 cites W2155013181 @default.
• W2611492720 cites W2158923004 @default.
• W2611492720 cites W2160443692 @default.
• W2611492720 cites W2167211494 @default.
• W2611492720 cites W2170472282 @default.
• W2611492720 cites W2178177034 @default.
• W2611492720 cites W2181084192 @default.
• W2611492720 cites W2189619102 @default.
• W2611492720 cites W2224761081 @default.
• W2611492720 cites W2460264116 @default.
• W2611492720 cites W4243177274 @default.
• W2611492720 doi "https://doi.org/10.1152/ajpheart.00014.2017" @default.
• W2611492720 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5538861" @default.
• W2611492720 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28476919" @default.
• W2611492720 hasPublicationYear "2017" @default.
• W2611492720 type Work @default.
• W2611492720 sameAs 2611492720 @default.
• W2611492720 citedByCount "11" @default.
• W2611492720 countsByYear W26114927202017 @default.
• W2611492720 countsByYear W26114927202018 @default.
• W2611492720 countsByYear W26114927202019 @default.
• W2611492720 countsByYear W26114927202020 @default.
• W2611492720 crossrefType "journal-article" @default.
• W2611492720 hasAuthorship W2611492720A5017952950 @default.
• W2611492720 hasAuthorship W2611492720A5024268930 @default.
• W2611492720 hasAuthorship W2611492720A5053447036 @default.
• W2611492720 hasAuthorship W2611492720A5078998559 @default.
• W2611492720 hasAuthorship W2611492720A5082946065 @default.
• W2611492720 hasBestOaLocation W26114927201 @default.
• W2611492720 hasConcept C126322002 @default.
• W2611492720 hasConcept C134018914 @default.
• W2611492720 hasConcept C142724271 @default.
• W2611492720 hasConcept C164705383 @default.
• W2611492720 hasConcept C178853913 @default.
• W2611492720 hasConcept C204787440 @default.
• W2611492720 hasConcept C27081682 @default.
• W2611492720 hasConcept C2778198053 @default.
• W2611492720 hasConcept C2781072394 @default.
• W2611492720 hasConcept C42219234 @default.
• W2611492720 hasConcept C71924100 @default.
• W2611492720 hasConcept C72859922 @default.
• W2611492720 hasConcept C78085059 @default.
• W2611492720 hasConceptScore W2611492720C126322002 @default.
• W2611492720 hasConceptScore W2611492720C134018914 @default.
• W2611492720 hasConceptScore W2611492720C142724271 @default.
• W2611492720 hasConceptScore W2611492720C164705383 @default.
• W2611492720 hasConceptScore W2611492720C178853913 @default.
• W2611492720 hasConceptScore W2611492720C204787440 @default.
• W2611492720 hasConceptScore W2611492720C27081682 @default.

• next